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Abstract
Background
The main objective of the TAK project is investigating barriers in accessing HIV care after
HIV-diagnosis at the CBVCTs of central Poland. Here we describe factors associated with
and changes over time in linkage to care and access to cART.
Method
Data collected in 2010–2013 in CBVCTs were linked with HIV clinics records using unique
identifiers. Individuals were followed from the day of CBVCTs visit until first clinical visit or
4/06/2014. Cox-proportional hazard models were used to identify factors associated with
being linked to care and starting cART.
Results
In total 232 persons were diagnosed HIV-positive and 144 (62.1% 95%CI: 55.5–68.3) per-
sons were linked to care. There was no change over time in linkage to care (p = 0.48), while
time to starting cART decreased (p = 0.02). Multivariate factors associated with a lower rate
of linkage to care were hetero/bisexual sexual orientation, lower education, not having an
HIV-positive partner and not using condoms in a stable relationship. Multivariate factors
associated with starting cART were lower education, recent year of linked to care, and first
HIV RNA and CD4 cell count.
Conclusions
Benefits of linkage to care, measured by access to early treatment, steadily improved in
recent years. However at least 1 in 3 persons aware of their HIV status in central Poland
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remained outside professional healthcare. Persons at higher risk of remaining outside care,
thus target population for future interventions, are bi/heterosexuals and those with lower
levels of education.
Introduction
It is estimated that up to 50% of HIV positive persons in Europe are unaware of their HIV
infection and half of those newly diagnosed present late for care in Central and Eastern Europe
[1–3]. Early diagnosis and initiation of combination antiretroviral therapy (cART) reduce mor-
bidity and mortality to a significant degree, as well as reducing rates of onward HIV transmis-
sion and health care costs [4, 5].In order for this to occur, two crucial conditions must be met:
firstly HIV should be diagnosed in a timely manner and secondly the patient should present to
and be retained in medical care [6–8].
Increased HIV testing and strengthening of care pathways are encouraged in all settings.
WHO and ECDC both recommend decentralization and diversification of HIV testing systems
at both local and national levels [9]. This presents new challenges for linkage and engagement
in HIV care, but there are few guidelines addressing this point [10]. Linkage to care remains an
under investigated element in the continuum of care. Research into prompt linkage to and suc-
cessful retention in HIV care in Central and Eastern Europe is limited, despite being
highlighted as an important area for improving the quality of HIV care and containing the epi-
demic [11].
The Test and Keep in Care (TAK) project was initiated in response to the above, focusing
on linkage to care of people who test HIV positive at three community-based voluntary coun-
selling and testing facilities (CBVCTs) in central Poland. The main objective of the project is to
estimate the proportion of HIV-positive persons linked and retained at each stage of HIV care
and to investigate related factors in order to target effective interventions for linkage to care.
The preliminary results indicated that significant proportion of patients were not linked to care
[12]. Here we investigate factors associated with linkage to care and access to cART between
2010 and 2013 and describe changes in rates over time.
Method
Study methods
The detailed study methods were published elsewhere [12]. Briefly, data collected between 1/1/
20110 and 31/12/2013 in three CBVCTs were linked with HIV clinics’ records usingWestern
blot test number as the unique identifier. All persons tested HIV-positive receive detailed infor-
mation about HIV specialist clinics where they can make an appointment over the phone or in
person. Each person arriving at the clinic is seen by an HIV specialist immediately or at the
time of his/hers choice and a personalizedmedical record is started. Persons registered in HIV
clinics are followed routinely according to standards of medical care set by the European and
Polish AIDS Societies [13].
Data collected in the study include pre-clinical data, which is self-reported by CBVCT cli-
ents on questionnaires standardised by National AIDS Centre. Information collected includes:
nationality, level of education, sexual orientation, whether any HIV test had been performed
previously and its location, number of tests within last year, year of test(s), details about sexual
contacts, if ever tested for STI, hepatitis B and C, if partner was tested for HIV, if partner is
HIV-positive, whether client was in a stable relationship within last year, condom use with
Linkage to Care—Data from Test and Keep in Care (TAK) Project
PLOS ONE | DOI:10.1371/journal.pone.0162739 October 6, 2016 2 / 13
Competing Interests: The authors of this paper
declare no conflict of interest.
stable partners and/or casual partners, number of stable and/or casual partners. This informa-
tion is self-assessed by the CBVCT client, for example “stable relationship” reflects the client’s
perspective and is not pre-defined. Clinical data includedmedical information collected by
HIV clinics as part of routine healthcare.
Patients and Inclusion criteria
People who were diagnosedHIV-positive in CBVCTs between 1/1/2010 and 31/12/2013 were
included in the analysis. For the purpose of this study CBVCT clients who had a reactive HIV
screening test (fourth generation test) were considered HIV-positive. Linkage to care was
defined as date of first visit in the HIV clinic. Persons who tested HIV-positive, but failed to
return to CBVCT for confirmatoryWestern-blot test, did not collected the confirmatory test or
did not agree to de-coding of the confirmatory test were considered lost to care. Individuals
were followed from the date of CBVCTs visit until earliest of first clinical visit or 4/06/2014.
Patients who were linked to care were further followed to determine whether they com-
menced cART (defined as receiving three or more antiretroviral drugs [ARVs]), from date of
first clinical visit until date of first cART or 4/06/2014.
Ethical approvals
The study has been approved by the Bioethical Committee of the Medical University of War-
saw (AKBE/99/16). Due to the anonymous character of CBVCT testing informed consent was
not collected.
Statistical analyses
Baseline characteristics of those who were linked to care and commenced cART were sepa-
rately compared to those who were not using chi-squared test for categorical andWilcoxon-
Mann-Whitney for numerical variables. Kaplain-Meier estimates and log-rank tests were used
to compare the rates of linkage to care and starting cART by year. Cox-proportional hazard
models were used to identify factors associated with being linked to care (baseline date was
HIV test date) and starting cART (baseline date was first visit in HIV clinic). Variables that
were significant in the univariate analysis (defined as P-value <0.1) were adjusted for in the
multivariate analysis. Variables considered for inclusion in both models were age at HIV test,
gender, nationality, education, sexual orientation, test location, number of tests within last
year, year of test, sexually transmitted infections, whether the partner was tested, whether part-
ner was HIV-positive, if in a stable relationship within the last year, condom use with stable
partners, condom use with casual partners, number of stable partners ever and in the last year,
number of casual partners ever and in the last year. Additional variables considered for inclu-
sion in the model for commencing cART; were measured at baseline and were Hepatitis B
(HBV) and Hepatitis C (HCV) status, syphilis, HIV RNA level, lymphocyte CD4+ count, as
well as CD3+, CD8+ and CD4+/CD8+ ratio. Correlation between clinical variables (HIV RNA
level, CD4+ at first visit,CD3+, CD8+, CD4+/CD8+ ratio at first visit) were assessed using
Spearman’s rho.
All statistical tests were two sided and a type I error rate of 5%. All statistical analyses were
performed using SAS 9.3 (Statistical Analysis Software, CaryNC, USA).
Results
In the study period, between 1/1/20110 and 31/12/2013, 232 persons were diagnosedHIV-pos-
itive in three CBVCTs. They were mostly Polish (96.1%), living in the central region of Poland
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(94.0%) and having higher education (77.6%). Among them 94.8% were male, 75.4% were men
having sex with men (MSM), 22.8% had a HIV-positive partner, 11.6% were in a stable rela-
tionship and 36.2% had a partner who ever tested for HIV. Median age was 30.1 (IQR: 25.2–
35.9) years.
Linkage to care
One hundred and forty four (62.1% with 95%CI: 55.5%–68.3%) persons were linked to care. Of
those who were linked to care, 68.8% of linked patients registered within one month and 81.3%
registered within three months from testing. There was no change over time in the proportion
of persons linked to care (global p = 0.48) (Table 1, Fig 1A). The median time from the date of
HIV test till first visit in HIV clinic was 0.6 (0.4–1.1) and till first lymphocyte CD4+measure-
ment was 0.6 (IQR: 0.4–1.0) months.
Persons linked to care were o more likely to beMSM (83.3% vs. 62.5%; p<0.01), have an
HIV-positive partner (27.8% vs. 14.8%;p = 0.02), to be using condom in a stable relationship
(48.6% vs. 34.1%;p = 0.031) and less likely to remain in a stable relationship within last year
(8.3% vs. 17.0%;p = 0.05) as compared to persons not linked to care. Other pre-clinical charac-
teristics did not differ significantly (Table 1).
In univariate models lower or unknown level of education (Hazard ratio [HR] = 0.70; 95%
confidence interval [95%CI]: 0.46,1.06), bi- or heterosexual orientation (0.48; 0.31,0.75), having
HIV-negative or HIV unknown status partner (0.67;0.46,0.96) and not using condoms with
stable partner (0.68; 0.49,0.94) significantly decreased the chance of being linked to care. Older
age was increasing the chance of being linked to care (HR per 10 years older: 1.29; 1.07,1.55)
(Fig 2). After adjustment for age and factors with P<0.1, the chance of being linked to care was
lower in those who were of bi- or heterosexual orientation (0.47; 0.25,0.87), lower or unknown
level of education (0.58; 0.37,0.91) and not using condoms with stable partner (0.60; 0.43,0.85).
Age remained the factor significant improving the likelihood of linkage by 61% per 10 years
older (1.61; 1.30,2.00) (Fig 2). The median age at HIV test was 27.4 (IQR:24.2–34.1) years for
those not linked and 30.4 (27.1–36.1) years for those linked to care. HIV status of partner, and
being in a stable relationship were no longer significant after adjustment.
Starting cART
Among the 144 people who were linked to care, 117 (81.3%) started cART during 118 person-
years of follow up. The median follow-up per person was 5 (95% CI: 1–16) months.
The median age at first visit at the HIV clinic was 30.6 (IQR: 27.1,36.3) years. The median
baseline lymphocyte CD3+ count was 1315 (1071, 1736) cells/μl, CD4+ count was 394
(292,507) cells/μl, CD8+ count was 850 (608,1182) cells/μl, median lymphocyte CD4+/CD8
+ ratio was 0.4 (0.3,0.7) and HIV RNA 4.5 (3.9, 5.1) log10 copies/ml. In terms of co-infections
3 (2.1%) patients were anti-HCV positive, 16 (11.1%) of patients had HBV infection in the past
but none had positive HBs antigen and 30 (20.8%) had positive Venereal Disease Research Lab-
oratory test (VDRL) (Table 2).
Pre-clinical characteristics were comparable between patients who started and not yet
started cART. In terms of clinical characteristics, patients who started cART were more likely
to have HIV RNA above 10 000 copies/ml (79.5% vs. 40.7%, p<0.01) and lymphocyte CD4
+ count below 350 cells/μl (40.2% vs. 7.4%, p<0.01). They did not differ significantly in respect
to VDRL, anti-HCV or anti-HBc total antibody statuses. There were 3 people who were HCV
positive at baseline, all of whom started cART. Due to low numbers baseline HCV status was
not considered for inclusion in cox models.
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Table 1. Baseline pre-clinical characteristics for those who were linked to care and for those who started cART.
Linked to care Started cART
Factors Total n (%) no yes p-value Total n (%) no yes p-value
All 232 (100) 88 (100) 144 (100) 144 (100) 27 (100) 117 (100)
Age at first visit
< = 30 116 (50.0) 50 (56.8) 66 (45.8) 0.10 63 (43.8) 12 (44.4) 51 (43.6) 0.94
>30 116 (50.0) 38 (43.2) 78 (54.2) 81 (56.3) 15 (55.6) 66 (56.4)
Sex
Male 220 (94.8) 83 (94.3) 137 (95.1) 0.78 137 (95.1) 25 (92.6) 112 (95.7) 0.50
Female 12 (5.2) 5 (5.7) 7 (4.9) 7 (4.9) 2 (7.4) 5 (4.3)
Nationality
Polish 223 (96.1) 83 (94.3) 140 (97.2) 0.28 140 (97.2) 27 (100) 113 (96.6) 0.98
Other 9 (3.9) 5 (5.7) 4 (2.8) 4 (2.8) 0 (0.0) 4 (3.4)
Education
high 180 (77.6) 63 (71.6) 117 (81.3) 0.09 117 (81.3) 22 (81.5) 95 (81.2) 0.97
lower than high/unknown 52 (22.4) 25 (28.4) 27 (18.8) 27 (18.8) 5 (18.5) 22 (18.8)
Sexual orientation
Homosexual 175 (75.4) 55 (62.5) 120 (83.3) < .001 120 (83.3) 20 (74.1) 100 (85.5) 0.16
Bi/heterosexual 57 (24.6) 33 (37.5) 24 (16.7) 24 (16.7) 7 (25.9) 17 (14.5)
Test location
CBVCT 128 (55.2) 44 (50.0) 84 (58.3) 0.22 84 (58.3) 18 (66.7) 66 (56.4) 0.33
Other 104 (44.8) 44 (50.0) 60 (41.7) 60 (41.7) 9 (33.3) 51 (43.6)
Number of ests within last year
None 65 (28.0) 25 (28.4) 40 (27.8) 0.92 40 (27.8) 6 (22.2) 34 (29.1) 0.48
1+ 167 (72.0) 63 (71.6) 104 (72.2) 104 (72.2) 21 (77.8) 83 (70.9)
Year of test
2010 32 (13.8) 14 (15.9) 18 (12.5) 0.57
2011/10 76 (32.8) 31 (35.2) 45 (31.3) 60 (41.7) 11 (40.7) 49 (41.9) 0.94
2012 70 (30.2) 22 (25.0) 48 (33.3) 45 (31.3) 8 (29.6) 37 (31.6)
2013 54 (23.3) 21 (23.9) 33 (22.9) 40 (27.1) 8 (29.6) 31 (26.5)
Sexually transmitted infection
No/unknown 197 (84.9) 77 (87.5) 120 (83.3) 0.39 120 (83.3) 20 (74.1) 100 (85.5) 0.16
Yes 35 (15.1) 11 (12.5) 24 (16.7) 24 (16.7) 7 (25.9) 17 (14.5)
Partner tested
No/unknown 148 (63.8) 56 (63.6) 92 (63.9) 0.97 92 (63.9) 20 (74.1) 72 (61.5) 0.23
Yes 84 (36.2) 32 (36.4) 52 (36.1) 52 (36.1) 7 (25.9) 45 (38.5)
Partner HIV+
No/unknown 179 (77.2) 75 (85.2) 104 (72.2) 0.02 104 (72.2) 18 (66.7) 86 (73.5) 0.48
Yes 53 (22.8) 13 (14.8) 40 (27.8) 40 (27.8) 9 (33.3) 31 (26.5)
In a stable relationship within last year
No/unknown 205 (88.4) 73 (83.0) 132 (91.7) 0.05 132 (91.7) 24 (88.9) 108 (92.3) 0.56
Yes 27 (11.6) 15 (17.0) 12 (8.3) 12 (8.3) 3 (11.1) 9 (7.7)
Condom use with stable partners
Yes 100 (43.1) 30 (34.1) 70 (48.6) 0.03 70 (48.6) 12 (44.4) 58 (49.6) 0.63
No/unknown 132 (56.9) 58 (65.9) 74 (51.4) 74 (51.4) 15 (55.6) 59 (50.4)
Condom use with casual partners
Yes 132 (56.9) 47 (53.4) 85 (59.0) 0.40 85 (59.0) 16 (59.3) 69 (59.0) 0.98
No/unknown 100 (43.1) 41 (46.6) 59 (41.0) 59 (41.0) 11 (40.7) 48 (41.0)
Number of stable artners
(Continued )
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The time to starting cART decreased over calendar time and the percentage of patients who
started cART within one year from their first visit in the clinic increased (Fig 1B).
In univariate models lower or unknown level of education (HR: 1.87; 95%CI: 1.16,3.01),
more recent year of being linked to care (1.77; 1.12,2.80 for 2012, and 2.99; 1.79,4.99 for 2013/
14), no condom use with casual partner (1.59; 1.08,2.33) and higher HIV RNA at baseline (HR
per 10-fold higher: 1.79; 1.39,2.30) significantly increased the chance of starting cART. Chance
of starting cART was lower in those with a higher number of casual partners (HR for>21 part-
ners relative to 1–5 or unknown: 0.36; 0.15,0.87) and a higher CD4 count (0.69; 0.62,0.76). In
univariate analysis, those with lower CD3+ lymphocyte count (HR per 2 fold higher: 0.61;
0.46,0.81) and CD4+/CD8+ (HR per 1 unit higher: 0.16; 0.07,0.36) ratio had lower chance of
starting cART. However, these variables were not included in adjusted analyses due to high
correlation with CD4+ lymphocyte count (Spearman’s rho: 0.54 and 0.66, respectively).
After adjustment, only year of being linked to care, number of causal partners, baseline
CD4+ count and baseline HIV RNA level remained significant. Persons linked to care in 2012
and in 2013/14 had respectively 76% and 137% higher chance of starting cART relative to
those linked in 2010/11 (HR: 1.76; 1.05,2.93 and 2.37; 1.26,4.44—respectively). Persons with
more than 20 casual partners had 60% lower chance of starting cART as compared to those
having 5 or fewer lifetime partners (0.40; 0.16,0.98). The chance of starting cART was 69%
higher for each 10 fold increase in HIV RNA (1.69; 1.30,2.19) and 27% lower for each doubling
of CD4+ count (0.73; 0.66,0.82), Fig 3.
Discussion
We have identified that 62.1% of people are linked to care after receiving a HIV diagnosis at
CBVCTs in Central Poland and this has not improved over recent years. This proportion is
lower than inWestern European countries. For example in United Kingdom in 2011 the pro-
portion of persons diagnosed and linked to care within one and three months were 88% and
97%, respectively [14]. Lower rates were reported in 2010 by seven autonomous regions of
Spain where 75.7% of 1769 newHIV positive persons were linked to care within 3 months after
diagnosis and 83.1% had evidence of linkage to care within a year [15]. High rates of linkage
were reported among Portuguese MSM through an online surveywith 97% of HIV positive
respondents reporting visiting a health professional within 6 months from positive test result
[16]. However in this surveymost persons were tested in primary care settings, thus reflecting
referral by a health professional to the HIV setting.
A comparison presented by Raymond et al. in 2014 confirmed large disparities in HIV treat-
ment cascades across five European countries with the highest rate of linkage to care i.e. 81% in
Denmark and the poorest i.e. 44% in Georgia [17–19].
Table 1. (Continued)
Linked to care Started cART
Factors Total n (%) no yes p-value Total n (%) no yes p-value
1–5,unknown 67 (28.9) 29 (33.0) 38 (26.4) 0.55 38 (26.4) 6 (22.2) 32 (27.4) 0.81
6–20 93 (40.1) 34 (38.6) 59 (41.0) 59 (41.0) 11 (40.7) 48 (41.0)
>21 72 (31.0) 25 (28.4) 47 (32.6) 47 (32.6) 10 (37.0) 37 (31.6)
Number of casual partners
1–5,unknown 176 (75.9) 69 (78.4) 107 (74.3) 0.49 107 (74.3) 19 (70.4) 88 (75.2) 0.53
6–20 40 (17.2) 12 (13.6) 28 (19.4) 28 (19.4) 5 (18.5) 23 (19.7)
>21 16 (6.9) 7 (8.0) 9 (6.3) 9 (6.3) 3 (11.1) 6 (5.1)
doi:10.1371/journal.pone.0162739.t001
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However comparison of published data is difficult due to the lack of a standard definition of
linkage to care. For example BHIVA guidelines recommend that newly diagnosed individuals
should expect to have their HIV fully assessed by appropriately trained staff within 2 weeks of
receiving an HIV-positive test result or to have CD4 result within one month [10]. Time till
first CD4+ count test can be an accurate outcome measure for healthcare settings where such
tests are immediately available. This may not be the case for low or middle income countries,
Fig 1. a. Kaplan-Meier plot for linked to care, stratified by year of HIV test b. Kaplan-Meier plot for starting
cART by year of linked to care.
doi:10.1371/journal.pone.0162739.g001
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therefore in 2011 WHO proposed a unified definition of linkage to care as duration of time
from diagnosis to enrolment in HIV care or treatment [20]. However often countries use a
combined definition e.g. timespan between documented clinical visit (CD4 cell count or HIV-1
viral load measurement) after HIV diagnosis, used by Chkhartishvili et al. [19].
Moreover the rates cannot be expected to be comparable for different settings.We found
that 62.1% of persons tested anonymously at CBVCTs located outside medical facilities were
linked to care, but this may not be representative of testing performed in medical settings.
Moreover as observedby a pan-European project, namely the HIV-COBATEST, there is an
important heterogeneity among CBVCTs [21]. It can be expected that rates of linkage to care
after a positive HIV test at facilities which also test for other sexually transmitted diseases or
are located at HIV clinics will be higher. However these facilities might be less frequented by
people less open about their sexual orientation or behaviours.
In our study being bi- or heterosexual decreased the chance of being linked to care by
approximately 50% and people with lower/unknown level of education by 40%, showing this is
an focal group for future interventions, importantly as this group has been previously identified
as more likely to be late presenters [2]. Factor increasing the chance of being linked to care was
age, with 60% increase by each 10 years older. The median age at HIV test in our study was
30.1 years with 25% of clients being younger than 25.2 years. This implies younger clients
should be consider at risk of not being linked.
In addition persons not using condoms with stable partner had a 40% lower chance of link-
age, which is consistent with our previous findings, although the reasons are unclear [12].
In our study over 80% of persons linked to care subsequently started cART. Persons regis-
tered in the clinic in 2012 and 2013/4 had 76% and 137% respectively higher chances of starting
cART relative to those registered in 2010/11. This suggests clinical decisionmaking has been
Fig 2. Adjusted and unadjusted hazard ratios for being linked to care in those tested for HIV at CBVTC.
doi:10.1371/journal.pone.0162739.g002
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influenced by recent evidence from the HIV Prevention Trials Network (HPTN) Study 052
and START Study, supporting the benefit of cART initiation regardless of lymphocyte CD4+
count from both individual and population perspectives [4, 22]. It could also reflect a change
in perception of the use of cART with easier to adhere and less toxic treatment alternatives
[23, 24].
An interesting observation is the unexpected relationship between level of education and
the chance of being linked to care and starting treatment. Persons with low/unknown level of
education had a 42% lower chance of being linked to care, yet those who were linked to care
had a 116% higher chance of starting cART. A large number of people who started cART had
Table 2. Additional baseline clinical characteristics for those who started cART.
Started cART
Factors Total n (%) no yes p-value
HBV at first visit
Yes 16 (11.1) 5 (18.5) 11 (9.4) 0.40
No 103 (71.5) 18 (66.7) 85 (72.6)
Unknown/missing 25 (17.4) 4 (14.8) 21 (17.9)
HCV at first visit
Yes 3 (2.1) 0 (0.0) 3 (2.6) 0.78
No 125 (86.8) 25 (92.6) 100 (85.5)
Unknown/missing 16 (11.1) 2 (7.4) 14 (12.0)
VDRL* test result at first visit
Yes 30 (20.8) 7 (25.9) 23 (19.7) 0.47
No/undetermined 100 (69.4) 19 (70.4) 81 (69.2)
Unknown/missing 14 (9.7) 1 (3.7) 13 (11.1)
HIV VL at baseline
0–10,000 40 (27.8) 16 (59.3) 24 (20.5) < .001
>10,000 104 (72.2) 11 (40.7) 93 (79.5)
Lymphocytes CD4+ at first visit (cells/μl)
1–350 49 (34.0) 2 (7.4) 47 (40.2) 0.005
351–500 58 (40.3) 12 (44.4) 46 (39.3)
>500 37 (25.7) 13 (48.1) 24 (20.5)
Lymphocytes CD3+ at first visit (cells/μl)
Missing 1 (0.7) 0 (0.0) 1 (0.9) 0.30
1–1000 29 (20.1) 4 (14.8) 25 (21.4)
1001–1500 63 (43.8) 9 (33.3) 54 (46.2)
>1501 51 (35.4) 14 (51.9) 37 (31.6)
Lymphocytes CD8+ at first visit (cells/μl)
Missing 1 (0.7) 0 (0.0) 1 (0.9) 0.91
1–700 54 (37.5) 9 (33.3) 45 (38.5)
701–1000 35 (24.3) 8 (29.6) 27 (23.1)
>1000 54 (37.5) 10 (37.0) 44 (37.6)
Lymphocytes CD4+/CD8+ Ratio
Missing 1 (0.7) 0 (0.0) 1 (0.9) 0.013
0.01–0.3 47 (32.6) 2 (7.4) 45 (38.5)
0.3–0.6 49 (34.0) 9 (33.3) 40 (34.2)
>0.6 47 (32.6) 16 (59.3) 31 (26.5)
* Venereal Disease Research Laboratory test
doi:10.1371/journal.pone.0162739.t002
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“unknown” education level, which prevented more detailed insight into this issue. However the
observeddiscordancemay reflect that persons from this group may struggle to be linked to
care, but once being under physician care they follow advice more strictly. A similar pattern
was previously describedwhere persons with lower/middle level of education were less likely to
have an HIV test [16].
Although only persons linked to care can fully benefit from being diagnosed, national sur-
veillance systems rarely address this important issue in many countries. In response, in May
2015WHO published the Strategic Information Guidelines for HIV in the healthcare system
where “know your epidemic” is the most important first step into fighting the HIV epidemic. It
is also highlighted that as much effort must be invested in linking/enrollingHIV-positive peo-
ple into care as is put into scaling up HIV testing services [25]. This study is unable to investi-
gate the impact of timely linkage to care and treatment initiation on outcomes. An important
addition to current surveillance system in Poland would be the development of unique patient
identifier/codingsystem which preserves anonymity while allowing for linkage of clinical data
and outcome measures throughout the pathway of care.
Fig 3. Adjusted and unadjusted hazard ratios for started cART in those who are tested.
doi:10.1371/journal.pone.0162739.g003
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There are some limitations which need to be mentioned. Firstly, we were not able to exclude
the possibility of some patients linking to care in another city or region of Poland. As the cen-
tral registration for newHIV infections in Poland is anonymous, we were not able to perform
external auditing. The majority of patients in TAK study are from the central region of Poland
and we rather see a trend towards centralization. Nevertheless we may have overestimated the
number of persons not linked to care. Secondly, information on reasons for HIV testing was
limited to sexual behaviours, which could have influence our understanding of possible barriers
to linkage. Finally, the observed increase in cART uptake over timemay be partially explained
by the change in patients perception of treatment risks and benefits.We are not aware how
many patients were offered cART and refused it and whether this has changed over time.
The majority of our study population were homosexual men, which may limit our ability to
form conclusions on other risk groups due to small sample sizes. However our study popula-
tion reflects the population of all HIV-positive persons in Poland and limited power due to low
numbers of women or bi-sexualmen will always be an issue [26].
Finally we based our study on routinely collected programmatic data, which has well recog-
nisedmethodological limitations. On the other hand this data provide valuable insight into
understanding the real-life scenario in public health, not only in Poland, but also in other Cen-
tral European countries with comparable settings.
In response to earlier TAK results, all CBVTC in Poland started recordingWestern blot test
numbers as unique identifier allowing for cross-checking with HIV clinics. It is very important
to further integrate this pragmatic data into surveillance systems [27].
Conclusions
There was no increase over time in linkage to care but the benefits of being linked to care, mea-
sured by access to early treatment, steadily improved in recent years. However, at least one in
three persons aware of their HIV status in central Poland remained outside HIV care. Persons
at higher risk of remaining outside care, thus target population for future interventions, are bi/
heterosexuals with lower level of education.
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